Case Report: Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination

Leerunyakul, Kanchana; Pakornphadungsit, Kallapan; Suchonwanit, Poonkiat

doi:10.3389/fmed.2021.752443

Cited by 19 publications

(18 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pityriasis rosea is a complication that appeared within 22 days and resolved within 12 weeks of vaccination [ 1 , 2 , 16 , 17 , 21 , 23 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 ]. It was associated with BNT162b2 vaccination in most patients (71.9%; 41 of 57 eruptions, Table 1 ).…”

Section: Resultsmentioning

confidence: 99%

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

et al. 2022

View full text Add to dashboard Cite

Because of the increasing emergence of cutaneous reactions from COVID-19 vaccines worldwide, we investigated the published reports of these complications. We searched the PubMed, Google Scholar, and Scopus databases and the preprint server bioRxiv for articles on cutaneous complications linked to mRNA-1273 (Moderna), BNT162b2 (Pfizer–BioNTech), and AZD1222 (AstraZeneca–Oxford University) vaccines published until 30 September 2021. Eighty studies describing a total of 1415 reactions were included. Cutaneous reactions were more prevalent in females (81.6%). Delayed large local reactions were the most common complication (40.4%), followed by local injection site reactions (16.5%), zoster (9.5%), and urticarial eruptions (9.0%). Injection site and delayed large local reactions were predominantly caused by the mRNA-1273 vaccine (79.5% and 72.0%, respectively). BNT162b2 vaccination was more closely linked to distant reactions (50.1%) than mRNA-1273 (30.0%). Zoster was the most common distant reaction. Of reactions with adequate information for both vaccine doses, 58.3% occurred after the first dose only, 26.9% after the second dose only, and 14.8% after both doses. Overall, a large spectrum of cutaneous reaction patterns occurred following the COVID-19 vaccination. Most were mild and without long-term health implications. Therefore, the occurrence of such dermatologic complications does not contraindicate subsequent vaccination.

show abstract

Section: Resultsmentioning

confidence: 99%

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…136 Moreover, 40 cases of pemphigoids have been described. [137][138][139][140][141][142][143][144][145][146][147][148][149][150][151] Regarding other cutaneous diseases developed following COVID-19 vaccination, 9, 40, 55, 12 and 11 cases of morphea, [152][153][154][155][156][157] pityriasis rosea, [158][159][160][161][162][163][164][165][166][167][168][169][170][171][172][173][174][175][176][177] herpes zoster, [178][179][180][181][182][183][184]…”

Section: Resultsmentioning

confidence: 99%

Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature

Battista¹,

Marasca²,

Genco³

et al. 2022

CCID

View full text Add to dashboard Cite

The outbreak of coronavirus disease 2019 represented a new worldwide challenge, strongly impacting on the global economy, overall health and lifestyle. Since then, several strategies have been adopted to contain the widespread of infection. Among these, vaccination is currently the most important measure to fight against the pandemic. However, several concerns such as slower-than-hoped-for rollout, the hurried approval with limited data, the mechanism of action (in particular mRNA-based), and the uncertain duration of protection they afforded were initially raised. Moreover, even if cutaneous reactions have been rarely reported in clinical trials, global mass vaccination showed several dermatologic reactions not initially recognized, leaving dermatologists to decide how to diagnose and treat them. In this scenario, dermatologists should be ready to promptly recognize these clinical manifestations. Thus, the aim of this manuscript is to review current literature on cutaneous reactions following COVID-19 vaccination, particularly inflammatory dermatological diseases, in order to help clinicians to better understand these dermatological conditions and to provide an extensive overview of all the vaccine-related skin manifestations.

show abstract

“…En el estudio de McMahon y colaboradores, describen hasta 13 patrones dermatológicos asociados con las vacunas, entre ellos casos de PR, la gran mayoría causados por las vacunas Moderna y Pfizer, las más ampliamente utilizadas [45]. Se han propuesto como mecanismos patogénicos, entre otros, una respuesta de hipersensibilidad retardada como respuesta a la vacuna, un aumento elevado de citoquinas que conduce a una desregulación inmunitaria y a la reactivación de virus herpes humanos, o una reacción en la piel mediada por mimetismo molecular entre la proteína spike que se genera por las vacunas y componentes del hospedero [41,[43][44][45][46][47].…”

Section: Discussionunclassified

Pitiriasis rosada como manifestación dermatológica de infección por SARS-CoV-2: a propósito de un caso

et al. 2022

View full text Add to dashboard Cite

Las manifestaciones cutáneas relacionadas a la infección por el coronavirus SARS-CoV-2, causante de COVID-19, se han descrito entre el 0,2% y 20,4% de las personas que cursan con esta enfermedad. Las más frecuentemente descritas son: lesiones maculopapulares (47%), lesiones acrales eritematosas con vesículas o pústulas (pseudoperniosis) (19%), urticariales (19%), lesiones vesiculosas (9%) y livedo/necrosis (6%). En particular, la pitiriasis rosada es una dermatosis autolimitada de etiología desconocida, sin embargo, se ha visto asociada a la infección por SARS-CoV-2, con algunos reportes de casos en la literatura. El mecanismo fisiopatológico de las lesiones cutáneas en COVID-19 no es claro, y se han planteado algunas teorías, entre las cuales está el papel que juega la enzima convertidora de angiotensina 2 (ACE2) utilizada por el virus para infectar las células, los infiltrados linfocíticos, los depósitos de factores del complemento en la piel, y la reactivación de virus latentes como los herpes virus humanos. Se presenta el caso de una paciente con pitiriasis rosada asociada a COVID-19 y se describen los casos reportados hasta la fecha.

show abstract

Case Report: Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination

Cited by 19 publications

References 18 publications

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature

Pitiriasis rosada como manifestación dermatológica de infección por SARS-CoV-2: a propósito de un caso

Contact Info

Product

Resources

About